The Pentagon has reinstated mandatory testosterone-deficiency screening for male active-duty and reserve service members aged 30 and older, lifting a temporary pause from earlier in September 2026. Defense Secretary Pete Hegseth and spokesperson Sean Parnell defend the initiative as a critical investment in warfighter lethality and readiness. However, the policy faces scrutiny from Representative Chrissy Houlahan, who questions its cost and intent, and clinical experts who warn of diagnostic complexities and the risks of unmonitored hormone therapy.
Pentagon testosterone screening reinstatement
- ▪The Defense Health Agency's updated guidance on testosterone screening lifted a temporary pause enacted in early September 2026 to allow for updates to the program.
- ▪The Pentagon issued updated clinical guidance on September 17, 2026, reinstating mandatory testosterone-deficiency screening for male active-duty and reserve service members aged 30 and older.
- ▪The Defense Health Agency's clinical practice guidelines for female service members are currently under review and will be released upon approval.
Diagnostic protocols for service members
- ▪Service members undergoing testosterone replacement therapy can deploy without a waiver if they demonstrate clinical stability and a testosterone level between 300 and 600 ng/dL during a four-to-six-week follow-up.
- ▪Male service members under the age of 30 will not undergo mandatory screening but can be tested upon request or if an examining provider identifies clinical indicators.
- ▪The Defense Health Agency's diagnostic protocol requires a second early-morning fasting test on a different day under identical pre-test conditions before a testosterone deficiency diagnosis is made.
Symptom assessment criteria
- ▪The Defense Health Agency's screening guidelines identify risk factors for testosterone deficiency, including obesity, type 2 diabetes, prior traumatic brain injury with loss of consciousness, and chronic opioid therapy.
- ▪The Defense Health Agency's screening protocol utilizes a structured assessment of symptoms, including erectile dysfunction, reduced sexual desire, unexplained muscle loss, and spontaneous morning erection loss.
Military readiness optimization rationale
- ▪Chief Pentagon spokesman Sean Parnell stated that proactively treating suboptimal hormone levels is an investment in warfighter health that strengthens performance and maximizes force readiness.
- ▪Defense Secretary Pete Hegseth announced the testosterone screening initiative in July 2026, stating it would optimize warfighter performance, resilience, and long-term health to maintain a tactical advantage.
Clinical expert concerns
- ▪Dr. Mohit Khera, a professor of urology at Baylor College of Medicine, warned that service members might bypass official testing and use unmonitored testosterone to avoid deployment waiver complications.
- ▪Dr. Helen Bernie, a urologist at Indiana University, emphasized that screening for testosterone deficiency is not equivalent to treatment and must lead to further evaluation to find underlying causes.
Story comments
Loading comments…